Empowered Funds LLC Trims Holdings in Novo Nordisk A/S $NVO

Empowered Funds LLC lowered its position in Novo Nordisk A/S (NYSE:NVO) by 35.8% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 54,188 shares of the company’s stock after selling 30,187 shares during the period. Empowered Funds LLC’s holdings in Novo Nordisk A/S were worth $1,991,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently bought and sold shares of NVO. Revolve Wealth Partners LLC lifted its position in Novo Nordisk A/S by 8.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock valued at $214,000 after purchasing an additional 200 shares during the period. AQR Capital Management LLC grew its position in Novo Nordisk A/S by 21.0% during the 1st quarter. AQR Capital Management LLC now owns 62,099 shares of the company’s stock worth $4,312,000 after purchasing an additional 10,758 shares during the period. Sivia Capital Partners LLC grew its position in Novo Nordisk A/S by 18.2% during the 2nd quarter. Sivia Capital Partners LLC now owns 10,320 shares of the company’s stock worth $712,000 after purchasing an additional 1,587 shares during the period. Invesco Ltd. raised its stake in shares of Novo Nordisk A/S by 26.3% during the 2nd quarter. Invesco Ltd. now owns 419,691 shares of the company’s stock valued at $28,967,000 after buying an additional 87,467 shares during the last quarter. Finally, Gamco Investors INC. ET AL acquired a new position in shares of Novo Nordisk A/S in the 2nd quarter valued at about $314,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Strong quarterly results and raised outlook: Novo Nordisk beat second-quarter revenue expectations by approximately 10% and adjusted EPS estimates by more than 20%. Revenue increased 7% year over year, operating profit rose 11%, and management lifted its 2026 sales and profit outlook for the second time this year. Novo Nordisk: The Market Has Lost Its Mind, Too Cheap To Ignore
• Positive Sentiment: Continued GLP-1 demand: International markets and obesity care continued to drive growth, while accelerating demand for the Wegovy pill supported the improved outlook. The company also retains substantial profitability and cash generation to fund research, development and shareholder returns. NVO Q2 Earnings Call Centers on Wegovy Pill and Outlook Lift
• Positive Sentiment: Patent enforcement win: A Dutch court ordered Ceban Ziekenhuisfarmacie to stop selling an infringing compounded semaglutide nasal spray, remove product listings and provide supply-chain information. The ruling could help protect Novo’s semaglutide franchise from unauthorized competition in the Netherlands. Novo Nordisk wins Dutch court injunction
• Neutral Sentiment: Novo declared a dividend of 0.5786 per share, payable August 25 to shareholders of record August 17. The reported 254% yield appears inconsistent with the stated dividend and should be treated cautiously pending confirmation. Novo Nordisk dividend and insider transactions announcement
• Negative Sentiment: Pipeline and competitive concerns remain the main overhang: Investors focused on weaker-than-expected Wegovy pill sales, a setback for the next-generation obesity treatment CagriSema, U.S. pricing pressure and the widening commercial lead of Eli Lilly’s GLP-1 portfolio. These issues overshadowed the earnings beat and guidance increase. The divide between Eli Lilly and Novo Nordisk is widening

Novo Nordisk A/S Price Performance

Shares of Novo Nordisk A/S stock opened at $45.90 on Friday. The stock has a market capitalization of $204.96 billion, a P/E ratio of 11.22, a PEG ratio of 4.06 and a beta of 0.76. The business has a 50 day simple moving average of $46.96 and a two-hundred day simple moving average of $45.01. Novo Nordisk A/S has a 12 month low of $35.12 and a 12 month high of $64.16. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Tuesday, June 30th. The company reported $0.94 earnings per share (EPS) for the quarter. Novo Nordisk A/S had a return on equity of 61.20% and a net margin of 35.36%.The firm had revenue of $11.98 billion for the quarter. As a group, analysts predict that Novo Nordisk A/S will post 3.39 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The firm also recently announced a dividend, which will be paid on Tuesday, August 25th. Shareholders of record on Monday, August 17th will be paid a dividend of $0.5786 per share. This represents a yield of 254.0%. The ex-dividend date of this dividend is Monday, August 17th. Novo Nordisk A/S’s payout ratio is 42.79%.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. Zacks Research lowered Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a report on Monday, July 13th. Wall Street Zen lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. BMO Capital Markets reaffirmed a “market perform” rating and set a $47.00 price objective on shares of Novo Nordisk A/S in a research note on Thursday. HSBC reaffirmed a “hold” rating on shares of Novo Nordisk A/S in a report on Monday, July 6th. Finally, Nordea Equity Research raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Friday, June 19th. Five analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Novo Nordisk A/S currently has an average rating of “Hold” and a consensus price target of $65.81.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.